DNLI stock: November 5 results date guides Denali Therapeutics stock

November 5, 2026 is the scheduled date for Denali Therapeutics' third-quarter results, with consensus revenue of USD 12.22 million and consensus earnings of minus USD 0.32 per share, according to MarketBeat. Denali Therapeutics stock was trading at EUR 16.56 at Lang & Schwarz on October 22, 2026 at 6:35 p.m. CEST.

Q3 estimates follow a weak quarter

The forecast would represent a sharp increase from second-quarter revenue of USD 3.60 million. Denali reported a diluted loss of USD 0.68 per share for the second quarter, wider than the USD 0.51 consensus loss, according to MarketBeat. The revenue comparison is the more constructive part of the latest operating picture.

Stock remains below its yearly high

On the Nasdaq, Denali Therapeutics was trading at USD 18.55 at 12:39 p.m. ET on October 22, 2026. Its market capitalization was USD 3.0 billion, while the one-year trading range stood at USD 13.75 to USD 27.30. The price-to-earnings ratio was minus 6.55, and the company paid no dividend.

November 5 is the next date

The third-quarter announcement is scheduled after the market closes, with a conference call set for 4:00 p.m. ET, according to MarketBeat. Denali is a biotechnology company developing treatments for neurodegenerative diseases and uses a blood-brain barrier transport platform, according to Denali Therapeutics.

Price and reporting date

The November report will put the USD 12.22 million revenue estimate against the USD 3.60 million reported for the second quarter. At Lang & Schwarz, the stock stood at EUR 16.56 on October 22, 2026 at 6:35 p.m. CEST after hours. The further course of trading is shown by the continuously updated real-time quote of Denali Therapeutics stock.

Market context: Market report S&P 500.

More news and analyses on Denali Therapeutics stock